Financial Performance - Revenue for the six months ended June 30, 2021, was HKD 737,374,000, representing a 128% increase from HKD 323,835,000 in the same period of 2020[12] - Gross profit for the same period was HKD 622,694,000, up 144% from HKD 254,710,000 year-on-year[12] - Profit before tax increased to HKD 183,074,000, a 216% rise compared to HKD 57,790,000 in the prior year[12] - Net profit for the period was HKD 162,186,000, compared to HKD 49,188,000 in the previous year, marking a 229% increase[12] - The total comprehensive income for the period was HKD 180,212,000, significantly higher than HKD 2,826,000 in the same period of 2020[12] - The profit for the six months ended June 30, 2021, was HKD 218,712,000, compared to HKD 69,667,000 for the same period in 2020, reflecting a growth of 213.5%[29] - The group’s profit for the period was approximately HKD 162.2 million, a 229.7% increase from approximately HKD 49.2 million in the same period last year[118] Assets and Liabilities - Total assets as of June 30, 2021, amounted to HKD 2,618,277,000, up from HKD 2,421,339,000 at the end of 2020[14] - The company's total liabilities increased to HKD 1,040,924,000 from HKD 995,148,000, reflecting a growth of 4.6%[14] - The net asset value of the company reached HKD 1,577,353,000, compared to HKD 1,426,191,000 at the end of 2020, indicating a 10.6% increase[14] - Cash and cash equivalents increased to HKD 657,754,000 as of June 30, 2021, compared to HKD 390,388,000 at the end of 2020, marking a growth of 68.6%[29] - The company’s total liabilities included convertible loans with a fair value determined to be insignificant as of June 30, 2021[79] Earnings and Dividends - Basic earnings per share for the period were HKD 0.2812, up from HKD 0.0851 in the same period last year[12] - The company declared an interim dividend of HKD 0.04 per ordinary share for the six months ended June 30, 2021, compared to no dividend in the same period of 2020[45] - The basic and diluted earnings per share for the six months ended June 30, 2021, were HKD 0.2812 and HKD 0.2738, respectively, based on a profit attributable to shareholders of approximately HKD 162.2 million[129] Cash Flow and Financing - Cash generated from operating activities increased significantly to HKD 209,824,000 in the first half of 2021, up from HKD 57,828,000 in the same period of 2020, reflecting improved operational efficiency[18] - The net cash used in financing activities was HKD (37,688,000) for the six months ended June 30, 2021, an improvement from HKD (43,955,000) in the same period of 2020[29] - The total financing cost for the period was approximately HKD 5.4 million, compared to HKD 3.4 million in the same period last year[121] Research and Development - The group has initiated a five-year R&D plan from 2021 to 2025 to enhance its R&D capabilities in the ophthalmology field[108] - The group is conducting multiple research and development projects at various clinical stages, including single-dose ophthalmic products and biologics[97] - Total R&D expenses amounted to approximately HKD 85.9 million, representing 11.7% of revenue, compared to 14.7% in the same period last year, with HKD 74.8 million capitalized[120] Market and Product Development - The company is focusing on expanding its market presence and enhancing its product offerings, as indicated by ongoing investments in new technologies and product development[19] - The estimated number of moderate to severe dry eye patients in China exceeded 117 million in 2019, indicating a significant market potential for the SkQ1 product[102] - The group has launched T-Bactum®, an antimicrobial oral care product, leveraging patented nano-emulsion technology[97] Employee and Management - The salary and other benefits paid to key management personnel amounted to HKD 4,827,000 for the six months ended June 30, 2021, compared to HKD 2,934,000 for the same period in 2020[93] - The group employed 1,308 full-time employees as of June 30, 2021, an increase from 1,242 full-time employees as of December 31, 2020[144] Corporate Governance - The audit committee reviewed the accounting principles and practices adopted by the group and discussed internal controls and financial reporting matters for the six months ended June 30, 2021[187] - The company has complied with the corporate governance code as per the listing rules throughout the review period[186] - All directors confirmed compliance with the standards set forth in the code regarding securities transactions during the six months ended June 30, 2021[191]

Financial Performance - For the year ended December 31, 2020, the company reported a consolidated revenue of approximately HKD 978.1 million, a decrease of 23.6% compared to the previous year, primarily due to a 44.3% decline in the first half of 2020 caused by COVID-19 control measures in China[11]. - The company's net profit after tax for the year was approximately HKD 218.9 million, down 27.6% from HKD 302.5 million in 2019, attributed to the impacts of COVID-19[13]. - The company's total assets increased by 16.5% to HKD 2,421.3 million, up from HKD 2,077.9 million in 2019[89]. - The company's gross profit margin improved slightly to 81.2% from 80.8% in the previous year[89]. - The distribution and selling expenses decreased by 24.7% to approximately HKD 476.6 million, aligning with the revenue decline[101]. - The company reported a total revenue of approximately HKD 978.1 million for the year ended December 31, 2020, representing a decrease of 23.6% compared to HKD 1,279.5 million in 2019[96]. - Net profit for the year was approximately HKD 218.9 million, down 27.6% from HKD 302.5 million in the previous year[101]. Revenue Segmentation - The ophthalmology segment contributed approximately HKD 419.2 million to the company's revenue, a decrease of 26.1%, while the surgical segment recorded total revenue of approximately HKD 558.9 million, a decrease of 21.5%[13]. - The bFGF product series accounted for approximately 83.3% of the total revenue for the group in the reviewed year[57]. - The ophthalmology segment contributed approximately HKD 419.2 million to the group's revenue, down 26.1% year-on-year[173]. - The surgical segment recorded total revenue of approximately HKD 558.9 million, a decrease of 21.5% compared to the previous year[173]. Research and Development - The company is investing in new products and technologies to enhance its product and R&D pipeline, focusing on ophthalmology and oncology as growth drivers[17]. - The company initiated a five-year R&D plan (2021-2025) to enhance its capabilities and position in the ophthalmology field, with 15 R&D projects in various stages, including 4 in clinical trial phases[34]. - The group has 15 R&D projects in various stages, with 4 ophthalmology projects currently in the IND/NDA stages[80]. - The group is advancing its pipeline under the enhancement program, with key projects in late-stage clinical development, including EB11-18136P for dry eye syndrome and EB12-20145P for wet age-related macular degeneration[167]. - The group has ongoing clinical research and development projects, including single-dose ophthalmic products and biologics involving growth factors and antibodies[61]. Strategic Partnerships and Agreements - A framework agreement was signed with Tibet Linzhi Baisheng Pharmaceutical Co., Ltd. for the potential acquisition of all intellectual property related to the development and production of various formulations of a specific product[18]. - The company entered into a co-development and exclusive licensing agreement with Shanghai Junshi Biosciences Co., Ltd. to develop a product for treating wet age-related macular degeneration, with a commitment to fund up to USD 24 million, covering 80% of development costs[18]. - The company entered an IP licensing agreement with Guangzhou Kangrui Biopharmaceutical Technology Co., Ltd. to develop and commercialize molecules for oncology treatment[22]. - The group entered into an IP licensing agreement with Guangzhou Kangrui Biopharmaceutical Technology Co., Ltd. to develop and commercialize therapeutic products for oncology[68]. Market Expansion - The company is expanding its market channels to Southeast Asia by establishing a base in Singapore[24]. - The company plans to leverage its investment in YesDok to expand into the Southeast Asian market, particularly Indonesia[181]. - The company aims to leverage online platforms for chronic disease patients through medical technology innovations[23]. Financial Position and Investments - As of December 31, 2020, the company's cash and cash equivalents amounted to approximately HKD 599.8 million, an increase from approximately HKD 473.3 million as of December 31, 2019[16]. - The group had bank credit facilities of approximately HKD 848.7 million, with HKD 434.1 million utilized[122]. - The group's cash and cash equivalents amounted to approximately HKD 599.8 million as of December 31, 2020, up from HKD 473.3 million as of December 31, 2019, representing a year-over-year increase of 26.7%[122]. - The total investment cost for the clinical development of the SkQ1 product with Mitotech S.A. amounted to approximately HKD 296,200,000, representing 12.2% of the total assets as of December 31, 2020[69]. - The actual investment cost for the co-development of licensed products with Fuhong Hanlin was approximately HKD 73,700,000, accounting for 3.0% of the total assets as of December 31, 2020[69]. Employee and Operational Insights - The total employee compensation for the year was approximately HKD 235.9 million, compared to HKD 214.5 million in the previous year, marking an increase of 9.9%[131]. - The group had 1,242 full-time employees as of December 31, 2020, an increase from 1,110 in 2019, representing a growth of 11.9%[131]. - The company has established a network of 43 regional sales offices in China, employing approximately 1,290 sales personnel, with about 38% being contract or agency staff[23]. - The company sells products to over 9,000 hospitals and medical institutions, as well as approximately 2,000 pharmacies in major cities, provinces, and counties in China[199]. Future Outlook and Challenges - The company anticipates rapid development in new drug discovery and development involving recombinant DNA technology and other pharmaceutical technologies[186]. - The COVID-19 pandemic continues to pose uncertainties regarding its potential financial impact on the company's operations and financial performance for the fiscal year ending December 31, 2021[188]. - Ongoing changes in local regulations and policies in China's healthcare and pharmaceutical sectors may significantly impact the company's operational performance and development prospects[187]. - The Chinese drug pricing system, controlled by the government, has led to a general decline in treatment drug prices over the past 20 years, potentially exerting downward pressure on drug prices and adversely affecting market share and profitability[186]. Corporate Social Responsibility - The company emphasizes environmental protection and aims to create an eco-friendly work environment through energy conservation and recycling initiatives[189]. - The company has been recognized with the "Most Socially Responsible Listed Company" award and ranked in the Forbes Asia Small and Medium Listed Companies list for 2020[71][72]. - The company has established long-term partnerships with multiple suppliers, ensuring compliance with quality and ethical commitments[198].

(ESSEX)1Z用 ESSEX BIO-TECHNOLOGY LIMITED 億 勝 生 物 科 技 有 限 公 司 (於開曼群島註冊成立之有限公司) (股份代號: 1061) 2020 中期報告 -- . 全球 . . · 生物再生科技 . 創先者 . 14. . . | --- | --- | --- | --- | --- | --- | |-------|---------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | . | | | | | | . | : | | | FSS FXT | | | | . . - | | | | | | . | . | | | | | | | | · . ● ● . . ● : ● -- 9 ● 億勝科技 再生未來 ● ● . ● ● . O . 0.0 III Do to ti on to the 目錄 億勝生物科技有限公司 二零二零年中期報告 1 2 公司資料 3 簡明綜合損益及其他全面收益表 4 簡明綜合財務狀況表 5 簡明綜合權益變 ...

Financial Performance - The company achieved a total revenue of approximately HKD 1,279,500,000 for the fiscal year ending December 31, 2019, representing an increase of 8.8% compared to the previous year, with a growth of 13.4% in RMB terms[30]. - The net profit for the year rose to approximately HKD 302,500,000, marking a significant increase of 30.9% year-on-year, with a 36.5% increase in RMB terms[30]. - The gross profit margin decreased to 80.8% from 82.8% in the previous year, while the net profit margin improved to 23.6% from 19.6%[19]. - Basic earnings per share increased by 29.1% to HKD 0.5229, while diluted earnings per share rose by 29.6% to HKD 0.5113[19]. - The interim dividend declared is HKD 0.035 per ordinary share, totaling HKD 20,247,745, an increase from HKD 0.03 per share and HKD 17,155,200 in the previous year[58]. - The company plans to distribute a final dividend of HKD 0.05 per ordinary share, pending approval at the upcoming annual general meeting[58]. - The company reported a total revenue of approximately HKD 1,279.5 million for the year ended December 31, 2019, representing an increase of 8.8% compared to HKD 1,176.5 million in 2018[135]. - Net profit for the year was approximately HKD 302,500,000, representing a 30.9% increase from HKD 231,100,000 in 2018[195]. - The ophthalmology segment contributed approximately HKD 567,500,000 to the total revenue, an increase of 7.3% compared to the previous year[195]. - The surgical segment recorded total revenue of approximately HKD 712,000,000, reflecting a 10.0% increase from the prior year[195]. Assets and Liabilities - The company's total assets increased by 43.3% to HKD 2,077,943,000, while total liabilities rose by 69.1% to HKD 880,798,000[18]. - Cash and cash equivalents amounted to approximately HKD 473,300,000, reflecting a 52.2% increase from the previous year[32]. - The company’s current ratio was reported at 2.49, indicating a slight decrease from 2.74 in the previous year[19]. - As of December 31, 2019, the group's bank borrowings amounted to HKD 220,000,000, an increase from HKD 55,000,000 in 2018, with an interest rate of 3.7%[142]. - The debt-to-asset ratio as of December 31, 2019, was 42.4%, compared to 35.9% in 2018[157]. Investments and Development - The company has invested approximately HKD 432.2 million in various clinical development projects, particularly in ophthalmology and oncology, since the initiation of its enhancement plan in 2015[38]. - The company has committed up to USD 20 million for the second phase of the Phase III clinical trial for the SkQ1 product, with the first patient being treated in December 2019[42]. - The company has entered into a conditional agreement to invest approximately USD 3.1 million in Antikor Biopharma Limited, which focuses on developing small antibody-drug conjugates for cancer treatment[43]. - The company has provided a convertible loan of RMB 15 million to Chengdu Shangong Medical Technology Co., with a conversion potential of approximately 15.4% equity[45]. - The company has established a wholly-owned subsidiary, EssexBio Therapeutics Inc., in the United States to serve as a research and development center and manage clinical trials[129]. - The company invested RMB 15,000,000 in a medical data analysis company focused on diabetic retinopathy, analyzing over 1,000,000 retinal images[200]. - The company acquired 100% equity in Wuhan Yadian Biotechnology Co., Ltd. for approximately RMB 1.2 million, focusing on minimally invasive medical technology[183]. Sales and Marketing - The bFGF product series accounted for 79.2% of total revenue, with the Beifu Shou series contributing 24.7% and the Beifu Ji series contributing 54.5%[30]. - The company has established 43 regional sales offices and employs around 1,300 sales personnel, including approximately 730 full-time employees[51]. - The company is focusing on developing online platforms for medical consultations and electronic prescriptions for chronic disease patients as part of its sales and marketing strategy[122]. - The average revenue generated by each salesperson and marketing representative increased by 10.4% to approximately HKD 984,000, reflecting effective sales and marketing management[140]. - The company has implemented sales and marketing strategies to penetrate lower-tier cities and develop online platforms for medical consultations and electronic prescriptions[51]. Research and Development - The company has a focus on research for new treatment solutions, particularly in oncology and ophthalmology targeted antibodies[56]. - Research and development expenses decreased to approximately HKD 32.6 million for the year ended December 31, 2019, down from HKD 35.1 million in 2018[141]. - The company has developed a blow-fill-seal platform to enhance its core competitiveness and produce preservative-free single-dose drugs, with four such products approved for registration and commercialization in China as of December 31, 2019[128]. - The flagship biopharmaceutical product rb-bFGF series is expected to maintain organic growth in the coming years, supported by expanded sales across major provinces in China and additional clinical plans[198]. Challenges and Future Outlook - Ongoing clinical trial programs may face delays due to the COVID-19 pandemic, which has been declared a global pandemic by the World Health Organization[57]. - The company is committed to taking necessary measures to overcome unforeseen difficulties arising from the pandemic[57]. - The Phase II trial was initially scheduled for completion in Q2 2020 but has been delayed to Q3 2020 due to the COVID-19 pandemic[199]. Corporate Governance - The management team has extensive experience in the pharmaceutical industry, with key members holding significant shares in the company[66][68][70][80]. - The group’s discretionary annual bonuses for directors are capped at 5% of the audited consolidated profit after tax and non-controlling interests, provided the profit exceeds HKD 50 million[168]. - The company has achieved significant recognition by being included in the MSCI China Small Cap Index, effective from May 28, 2019[36].

Financial Performance - Revenue for the six months ended June 30, 2019, was HKD 581.716 million, an increase of 3.6% compared to HKD 561.278 million for the same period in 2018[17]. - Gross profit for the same period was HKD 468.766 million, up from HKD 459.295 million, reflecting a gross margin improvement[17]. - Profit before tax increased to HKD 149.780 million, representing a 23.1% increase from HKD 121.641 million in the prior year[17]. - Net profit for the period was HKD 129.575 million, compared to HKD 98.916 million in the previous year, marking a 30.9% increase[17]. - Basic earnings per share rose to 22.39 HKD cents, up from 17.46 HKD cents, indicating strong earnings growth[17]. - Total comprehensive income for the period was HKD 140.691 million, significantly higher than HKD 82.217 million in the same period last year[17]. - The company reported a foreign exchange loss of HKD 2.670 million from the translation of overseas financial statements, compared to a loss of HKD 13.157 million in the previous year[17]. - Administrative expenses increased to HKD 34.219 million from HKD 24.904 million, reflecting higher operational costs[17]. - Financing costs rose to HKD 4.239 million, compared to HKD 3.397 million in the previous year, indicating increased borrowing costs[17]. Assets and Liabilities - Total assets increased to HKD 1,642,677 thousand, up from HKD 1,449,688 thousand, representing a growth of 13.3% year-over-year[19]. - Cash and cash equivalents rose to HKD 334,730 thousand, compared to HKD 311,098 thousand, reflecting an increase of 7.6%[19]. - Net current assets reached HKD 628,209 thousand, up from HKD 547,312 thousand, indicating a growth of 14.7%[19]. - Total liabilities increased to HKD 591,130 thousand, compared to HKD 520,787 thousand, marking a rise of 13.5%[19]. - Equity attributable to owners increased to HKD 1,051,547 thousand, up from HKD 928,901 thousand, showing a growth of 13.2%[19]. Segment Performance - As of June 30, 2019, the total external customer revenue for ophthalmic products was HKD 249,919, while for surgical products it was HKD 331,797, totaling HKD 581,716[44]. - The reported segment profit for the ophthalmic products was HKD 69,701 and for surgical products was HKD 92,195, leading to a total segment profit of HKD 161,896 for the six months ended June 30, 2019[44]. - The company reported a total segment profit of HKD 161,896 for the six months ended June 30, 2019, compared to HKD 130,781 for the same period in 2018, indicating a year-over-year increase[49]. Cash Flow and Investments - Operating cash flow before changes in working capital was HKD 161,202,000, an increase of 24% from HKD 129,891,000 in the same period last year[22]. - Net cash generated from operating activities was HKD 83,618,000, down from HKD 90,811,000 year-on-year[22]. - Total cash used in investing activities was HKD 76,332,000, compared to HKD 49,333,000 in the prior year, indicating a significant increase in investment outflows[22]. - The company incurred financing costs of HKD 4,239,000, an increase from HKD 3,397,000 year-on-year[22]. Research and Development - The company has developed five types of rb-bFGF biopharmaceuticals approved for sale in China, with three classified as national class 1 new drugs[130]. - The company is focusing on R&D and commercialization of preservative-free single-dose eye drops and other ophthalmic products[131]. - The company has maintained multiple R&D projects, some involving growth factors and antibodies for ophthalmic and respiratory diseases[131]. Acquisitions and Strategic Investments - The company acquired 100% equity of Wuhan Yadian Biotechnology Co., Ltd. for approximately HKD 1,400,000, with the main product being Carisolv for minimally invasive dental treatment[134]. - The company has committed to invest up to $16,500,000 (approximately HKD 129,700,000) in the clinical development of the SkQ1 product for dry eye disease[80]. - The company anticipates that the acquisition aligns with its expansion strategy in the dental and oral health sector[103]. Employee and Management Compensation - The total employee compensation for the period was approximately HKD 98,500,000, compared to HKD 68,500,000 in the previous period[178]. - The company reported a total remuneration of HKD 3,068,000 for key management personnel, slightly down from HKD 3,080,000 in the previous year[26]. Stock Options and Shareholder Information - The company has a total of 578,807,000 shares outstanding as of June 30, 2019, with a par value of HKD 0.1 per share[101]. - The total number of ordinary shares available for issuance under the plan is 25,375,000 shares, representing 4.38% of the issued share capital[184]. - The company issued 57,000 shares due to the exercise of stock options during the reporting period[181].

Financial Performance - The company achieved a consolidated revenue of approximately HKD 1,176,500,000 for the fiscal year ending December 31, 2018, representing a 30.8% increase from the previous year[16]. - The net profit for the year increased to approximately HKD 231,100,000, up 38.1% from approximately HKD 167,300,000 in the prior year[16]. - The gross profit margin was reported at 82.8%, slightly up from 82.0% in the previous year[11]. - The earnings per share (EPS) increased significantly, with basic EPS rising to HKD 0.4050 from HKD 0.2975, a growth of 36.1%[11]. - The profit for the year was approximately HKD 231.1 million, an increase of 38.1% compared to HKD 167.3 million in the previous year[108]. - The overall revenue contribution from ophthalmic products for the year ended December 31, 2018, was approximately HKD 529 million, representing a 20.8% increase from the previous year, driven by a 17.9% growth in the Beifu series[105]. - Surgical products recorded total revenue of approximately HKD 647.5 million for the year ended December 31, 2018, a 40.2% increase, primarily due to a significant 48.7% growth in the Beifuji series, although overall growth was tempered by a 52.9% decline in third-party product revenue[106]. - The flagship biopharmaceuticals generated revenue of approximately HKD 984.4 million, accounting for 83.7% of total revenue, with a year-on-year increase of 35.9, supported by sales expansion in second and third-tier cities in China[106]. Assets and Liabilities - The company's total assets reached HKD 1,449,689,000, a 25.0% increase from HKD 1,159,777,000 in the previous year[11]. - Total liabilities increased to HKD 520,787,000, up 23.9% from HKD 420,288,000 in the prior year[11]. - The company's cash and cash equivalents amounted to HKD 311,098,000, reflecting a 29.3% increase from HKD 240,627,000[11]. - The current ratio improved to 2.74 from 2.58, indicating better short-term financial health[11]. - The group’s debt-to-asset ratio as of December 31, 2018, was 35.9%, compared to 36.2% in 2017[123]. Investments and Development - The company plans to continue focusing on its core product lines while exploring opportunities for market expansion and new product development[16]. - The total investment committed to 12 entities/projects under the enhancement plan is approximately $53.9 million, with about $43.4 million already invested[23]. - The company has invested approximately $20 million in Chengdu Shangong Medical Technology Co., holding about 8% equity, to develop big data business in medical data analysis[22]. - The company is investing up to $16.5 million in a joint development agreement with Mitotech S.A. for the clinical development of SkQ1 eye drops in the U.S.[19]. - The company has invested approximately $5 million in MeiraGTx Limited, acquiring about 7.7% of its expanded issued preferred C shares[21]. - The group is currently discussing strategic cooperation with MeiraGTx Limited for future projects[149]. - The group is collaborating with Mitotech S.A. to develop eye drops containing SkQ1, which is undergoing Phase III clinical trials[149]. - The group has invested a total of USD 3,600,000 in Abpro Corporation and is discussing collaborative research projects[145]. Research and Development - The company has established a research and development platform focused on recombinant cell factors, particularly the development of recombinant basic fibroblast growth factor (bFGF) for wound healing products[97]. - Research and development expenses increased to approximately HKD 35.1 million, with about HKD 17 million capitalized, compared to HKD 27.1 million in the previous year[110]. - The group maintains a focus on R&D and clinical plans across multiple projects, particularly in ophthalmology and respiratory diseases[141]. Market Presence and Sales - The company has established 42 regional sales offices and approximately 1,320 sales personnel, including about 730 full-time employees and 590 contract or agency personnel[27]. - The company continues to expand its sales and distribution network, particularly in second- and third-tier cities in China, to maintain sustainable growth[75]. - The company’s products cover approximately 6,300 hospitals and medical institutions and about 1,000 pharmacies across major cities, provinces, and counties in China[142]. - The group successfully extended the distribution rights for Yixuean granules in China for a price of RMB 20,000,000[145]. Dividends and Shareholder Returns - The board declared an interim dividend of HKD 0.03 per ordinary share, totaling HKD 17,155,200, an increase from HKD 0.025 per share and HKD 14,055,525 in the previous year[35]. - The board proposed a final dividend of HKD 0.033 per ordinary share, pending approval at the upcoming annual general meeting[35]. - The company reported a mid-term dividend of HKD 0.03 per share paid on September 21, 2018, and proposed a final dividend of HKD 0.033 per share for the fiscal year ending December 31, 2018, subject to shareholder approval[136]. Strategic Challenges and Outlook - The Chinese drug pricing system, controlled by the government, has led to a general decline in treatment drug prices over the past 20 years, potentially exerting downward pressure on drug prices and adversely affecting market share, revenue, and profitability[164]. - The current healthcare reform in China is characterized by frequent changes in regulations, which may lead to significant adverse impacts on the company, including high costs and resource diversion[165]. - The group maintains an optimistic outlook for strong growth in the ophthalmology and surgical divisions in 2019[35]. Corporate Governance and Management - The company has a strong management team with over 24 years of experience in gene recombination technology and drug quality standards research[53]. - The company has appointed a new Chief Scientist with extensive experience in anti-tumor drug development, overseeing R&D in oncology, ophthalmology, and dermatology[55]. - The company provides competitive compensation and training opportunities to employees, aiming to be an attractive employer[172]. - The company’s success is partly reliant on the expertise and experience of its senior management and researchers, with potential adverse effects if key personnel leave[163].